After a year or more on it, you reached goal weight on a GLP-1. The number you wrote down at the start is the number on the scale this morning. Then the email arrives: the next refill ships Thursday at the same dose. Nobody has told you whether that dose is still the right one, a lower one, or none at all. You have heard about people who stopped and regained, and you have no plan for what comes next.
This piece follows one person through a first three months with GoodLife Health and sets out what a clinician would check, in what order, and why. Dana is a composite written for this article, not a real patient, and no lab result in the piece belongs to anyone. The question underneath is the one people ask before they join: is this only for weight loss? For Dana, the weight part is done. What remains is the part a membership is for.
- Goal weight is one reading; the next dose decision belongs to the markers behind it.
- The first panel adds ApoB, Lp(a), hs-CRP, fasting insulin and thyroid to what a basic panel reports.
- Hold, lower or stop is the clinician's decision, and the next quarterly panel tests it.
- GoodLife Health prescribes branded GLP-1 only and takes nothing on medication at any dose.
- $299 a month, $598 at sign-up; refunded in full if not accepted, non-refundable once accepted.
The refill that ships whether or not anyone asked
Dana is 44 and runs a regional sales team out of Denver. Dana started on compounded semaglutide through a $99-a-month app after a primary-care visit that lasted about as long as finding parking. That visit produced a basic panel, a glucose reading near the top of its range, and advice to cut back on sugar. The app produced a prescription within a day. Over fourteen months the dose went up on the schedule the emails set, the nausea of the early weeks faded, and the weight came off.
Now Dana is at goal, and the arrangement that got there has no next step. When Dana asked the app's chat about tapering, the reply was a template suggesting Dana raise it with a provider. The primary-care office offered an appointment weeks out, with a clinician Dana had never met. The refill keeps arriving at the same strength, because nothing in the subscription is set up to change it.
From the kitchen table, every option looks like a guess. Dana could stop and risk watching fourteen months reverse. Dana could stay and keep paying indefinitely for a dose nobody has chosen since the escalation schedule ran out. Or Dana could cut back alone, by stretching the time between doses, and hope. None of these is a medical decision, because none of them rests on anything measured since the first shipment arrived.
There is also the news. The FDA has published its concerns about unapproved GLP-1 drugs used for weight loss, compounded versions among them; the manufacturers have taken compounders to court; and reports have described dosing practices and added ingredients that differ from the approved products. Dana has read some of it and is unsure what it means for the vials in the refrigerator. We make no claim that a compounded drug is dangerous in itself. Those are the facts, and the plainest of them is that a clinician's license carries the responsibility for whatever is prescribed.
Dana did nothing wrong. The weight came off because the drug and the effort worked. The failure lies in the arrangement around them, which was built to start a prescription and keep it filled, with no one whose job is to decide when it should change.
What the scale measured, and what it never could
A GLP-1 is prescribed against weight, but the weight was sitting on top of a system. Cardiometabolic Optimization: The Definitive Guide sets out the chain: insulin resistance drives weight gain, visceral fat disrupts hormones, disrupted hormones stall metabolism, and a stalled metabolism feeds vascular inflammation. The scale reports the one link anyone can see from the bathroom.
The scale cannot tell Dana whether fasting insulin has come down, where ApoB sits, whether hs-CRP has moved, whether HbA1c has settled, or whether the thyroid is part of the story. A clinician wants those readings before deciding what a dose should do next, and in fourteen months nobody drew them. The last panel in Dana's record is the basic one from the short visit, which reported LDL and glucose and stopped there.
The trials that made these drugs well known are clear about what they measured. Semaglutide 2.4mg produced roughly 15% average body-weight loss over 68 weeks in STEP 1, and tirzepatide produced up to about 21% over 72 weeks in SURMOUNT-1. Those numbers describe weight lost on treatment. They do not tell one person, at goal, what dose comes next, or whether any does.
We do not know Dana's answer before the panel, and we would distrust anyone who claimed to. Hold, lower or stop might each be right for a different person at the same weight. The honest position is that the decision belongs to the markers and to a clinician who reads them over time. Whatever is chosen should be measured again in ninety days, not left to the next shipping email.
That is the answer to the question in this article. Weight loss is often the reason a person first looks at a membership. The membership itself is cardiometabolic primary care: a quarterly panel, one clinician who stays, and medication when it is indicated. Dana's weight is finished. The insulin, the lipids, the inflammation and the thyroid are the long haul, and they are what the fee pays to watch.
The field is already arranged for this. In September 2026 both makers of these drugs published their own self-pay prices, so branded medication now has a public price that is separate from any subscription. Testing before treating no longer requires a $20,000-a-year concierge practice. It requires a panel, a schedule and someone accountable for reading it. The eight-minute visit, once a year, was never built to run a feedback loop every ninety days.
Dana's first ninety days, month by month
Before anything clinical happens, there is a path, and not everyone reaches the end of it. Dana completes the eligibility check, then the intake, then the checkout, and then a clinician reviews the whole file and decides whether to accept Dana into care. If the answer were no, the $598 would come back in full. Once Dana is accepted, the first two months are non-refundable.
Dana's first ninety days (a composite)
| When | What happens | Why |
|---|---|---|
| Before day one | Eligibility check, intake, checkout, clinician's review | Not everyone is accepted; the clinician decides |
| Month one | First panel: ApoB, Lp(a), hs-CRP, HbA1c, fasting insulin, lipids, thyroid | The dose decision needs markers nobody has drawn |
| Month two | Video visit and messaging; the clinician decides hold, lower or stop | The decision rests on the results, read together |
| Month three | Second panel, around day ninety | The change is measured instead of assumed |
Month one: the panel comes before the decision
The first panel is drawn early. It includes ApoB, Lp(a), hs-CRP, HbA1c, fasting insulin and a full lipid panel, alongside thyroid markers (TSH, free T3, free T4) and whichever hormone markers the clinician judges relevant. Every result goes to Dana in full.
Medication is the question Dana arrived with, and the answer begins with what GoodLife Health does not do. We do not prescribe compounded GLP-1, at any dose, for anyone. If the clinician judges that a GLP-1 is still indicated, it will be a branded, FDA-approved product (Wegovy, Zepbound, Mounjaro or Ozempic). It is prescribed to the pharmacy Dana chooses and billed by that pharmacy at its own price, and GoodLife Health sets nothing, sees nothing and takes nothing on it. Whether Dana's insurance covers a branded drug is between Dana, the plan and the pharmacy. Prior authorization is the pharmacy's process, and we never promise its outcome.
For self-pay, the manufacturers' published prices are the reference. As of September 2026, NovoCare lists Wegovy pens at $199 a month for the first two fills (an introductory offer for new patients through December 2026) and $349 a month after, with the Wegovy pill from $149 a month at lower doses. LillyDirect lists Zepbound vials at $299 to $449 a month depending on dose. Those prices move with the dose. The membership fee does not.
A goal weight is one reading on one instrument. Before a dose is held, lowered or stopped, the clinician wants the markers the weight was standing in for, and wants them again ninety days after the change.
Month two: reading the numbers together
When the results are back, Dana and the clinician go through them on a video visit, marker by marker, with the old basic panel beside the new one. Questions that come up afterward go to the care team by message, so Dana does not have to save them for the next appointment.
The decision about the dose is made here, and it is the clinician's. It might be to hold the current dose, to lower it, or to stop. The definitive guide states the principle the model is built on: doses are held at the lowest effective level, and deprescribing, when the labs support it, counts as a success rather than a lost sale. If the panel raises a separate question, such as thyroid function or a hormone, it is worked up inside the same membership. Hormone therapy and thyroid medication are prescribed where indicated, with no separate tier, and the hormone pricing piece shows what those medications cost at the pharmacy. Nothing is promised in advance, including the outcome Dana most wants to hear.
Month three: the second panel tests the change
Around day ninety the next panel is drawn, and whatever was decided in month two is now measured. If Dana's markers hold on a lower dose, the plan has evidence behind it. If they drift, the clinician sees it within one quarter, well before any yearly visit would, and the plan is revisited with numbers instead of a feeling. From here the membership continues month to month at $299, and the panels keep coming four times a year, so the question of regain is watched instead of feared.
The dose you take at goal weight should be set by your markers, read by someone who is paid the same whether it goes up, down or to zero.
What changes about the money
Dana's app costs $99 a month, and the membership costs more. We will not argue that difference on price; the question worth asking is who earns what when the dose changes. Where the medication is part of the monthly price, the refill is the product, and a lower dose or no dose is a smaller sale. At GoodLife Health the fee is the same whatever medication is indicated and whatever the dose, including none, and nothing is taken on the drug. A clinician who lowers Dana's dose costs the company nothing, which is why it was built that way.
Depending on what is prescribed, the drug may well be the larger bill. The membership pays for the decision about it, and at goal weight that decision is the question Dana actually has.
The membership is $3,588 a year. It is generally eligible for HSA or FSA pre-tax dollars. It pairs with insurance for catastrophic coverage and does not replace it.
What to do before the next refill ships
Whether or not you join, three things are worth doing this week. Write down your starting weight, your current weight, your current dose and the date of each dose change, because that history is the first thing any clinician will ask for. Request copies of every lab drawn since you started the medication; if none were drawn, that is worth knowing too. Then ask whoever prescribes for you now what markers the next dose is based on, what the plan is at goal weight, and who decides when the dose changes.
If you already have a prescriber who draws ApoB, fasting insulin and the rest, reads them with you, and has a plan for the dose at goal, stay with that prescriber. You need someone accountable for a good answer, and that person does not have to be us. Whatever you decide about the dose, decide it with a clinician who has your numbers rather than alone at the kitchen table.
What we cannot tell you in advance is whether you will hold your weight on a lower dose, off the drug, or only on the dose you take now. We will not guess, and we will not promise a result. We can tell you that the question will be measured every quarter, by the same clinician, with every result in your hands.
Who this is not for
If you want the refill shipped at the lowest monthly price with no labs and no conversation, this membership is the wrong purchase, and a $99 app is the better fit. If you want to stay on a compounded GLP-1, we will not prescribe it. If you want a guarantee that you will never regain, nobody can honestly sell you one, and we do not. If you are looking for something to replace your health insurance, keep the insurance, because this sits beside it. And if you live outside the fifty states, we cannot see you.
For everyone else, here is the offer in full. The membership is $299 a month. $598 is charged at sign-up and covers the first two months, and after that it runs month to month. If the clinician cannot accept you into care, the $598 is refunded in full; once you are accepted, the first two months are non-refundable, and any medication follows the billing pharmacy's own return and refund policy. The fee buys four cardiometabolic panels a year with every result in your hands. It buys a clinician who stays with you by message and video, from a team licensed in all fifty states. And it buys medication prescribed when indicated to your pharmacy at that pharmacy's price, with nothing taken on it. In return you get the diagnosis a short visit never produced, your markers followed quarter over quarter, and an end to the eight-minute visit. One difference governs the rest: we test first and treat second, and we sell neither the drug nor the dose. If you are at goal weight with a refill on its way and no plan behind it, have the panel drawn before a shipping schedule makes the next dose decision for you.
Related Reading
- Cardiometabolic Optimization: The Definitive Guide
- Bioidentical Hormone Therapy at Pharmacy Cost: The Real Numbers
References
- NovoCare Pharmacy — Wegovy self-pay pricing (Novo Nordisk). 2026. www.novocare.com/pharmacy/wegovy.html
- Zepbound Self Pay Journey Program — LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/